Globus Medical, Inc. (NYSE:GMED) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET

Company Participants

Brian Kearns - SVP, Business Development & IR

Daniel Scavilla - President, CEO & Director

Keith Pfeil - SVP & CFO

Conference Call Participants

Matthew Miksic - Barclays Bank

Shagun Chadha - RBC Capital Markets

Vikramjeet Chopra - Wells Fargo Securities

Andrew Ranieri - Morgan Stanley

Jason Wittes - ROTH MKM Partners

Ryan Zimmerman - BTIG

Samuel Brodovsky - Truist Securities

Matthew O’Brien - Piper Sandler & Co.

Matthew Taylor - Jefferies

David Saxon - Needham & Company

Steven Lichtman - Oppenheimer

Richard Newitter - Truist Securities

Operator

Thank you for standing by, and welcome to the Globus Medical Third Quarter 2023 Earnings Call. [Operator Instructions].

I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations. Mr. Kearns, please go ahead.

Brian Kearns

Thank you, Leeway, and thank you, everyone, for being with us today. Joining today's call for Globus Medical will be Dan Scavilla, President and CEO; and Keith Pfeil, Chief Financial Officer. This review is being made available via webcast accessible through Investor Relations section of the Globus Medical website at www.globusmedical.com. .

Before we begin, let me remind that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2022 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today.

Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with Generally Accepted Accounting Principles or GAAP.

We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website.

With that, I'll turn the call over to Dan Scavilla, our President and CEO.

Daniel Scavilla

Thanks, Brian, and good afternoon, everyone. This quarter's earnings release will have a different format than our usual approach. On September 1, after clearing the FTC second request time frame, we executed the Globus NuVasive merger. With the timing of this event, we have a full third quarter revenue and financials for Globus, combined with the month of September only for NuVasive revenue and financials.